精品国产一区二区桃色

Journal News

From the journals: JBC

Isabel Casas
Nov. 4, 2022

A novel player involved in kidney injury response. The role of the Kaposi’s sarcoma-associated herpes virus in kinase pathway activation. Understanding what a linker does in heme extraction. Read about these papers recently published in the Journal of Biological Chemistry.

Novel player involved in kidney injury response

Fibrosis involves the excessive accumulation of extracellular matrix, which may result in loss of function when normal tissue is replaced by scar tissue, such as after injury. In the case of kidney disease in particular, fibrosis is the final step in chronic disease characterized by the accumulation of interstitial fibroblasts and myofibroblasts in addition to ECM accumulation.

Microscopy image of a mouse kidney section.
Carl Zeiss Microscopy
Microscopy image of a mouse kidney section.

Follistatin-like 1 is a secreted protein. While the role FSTL1 plays in heart and lung injury and development of fibrosis have been studied widely, the role this protein plays in kidney injury and progression to chronic disease remains to be determined.

In a in the Journal of Biological Chemistry, Yu Zhang and colleagues from the School of Biomedical Sciences at the Chinese University of Hong Kong and the Center of Nephrology and Urology at Sun Yat-sen University in China report that FSTL1 plays a profibrotic role in the kidney.

The team used several molecular biology and imaging techniques — including single-cell RNA-Seq analysis and immunofluorescence — to show that Fstl1 was enriched in stromal cells in obstructed mouse kidneys and that FSTL1 expression was induced in fibroblasts during kidney fibrogenesis in mice and in human patients.

In addition, the authors showed FSTL1 overexpression increased renal fibrosis and activated the Wnt/beta-catenin signaling pathway, whereas inhibition of FSTL1 lowered Wnt/β-catenin signaling.

A virus oncoprotein’s role in kinase pathway activation

The Kaposi’s sarcoma-associated herpes virus is the main etiological agent of Kaposi’s sarcoma, which manifests as patchy cancerous tumors on the skin and mucus membranes. It most often affects people with immune deficiencies, such as those with HIV/AIDS.

The virus — known as KSHV and human herpesvirus 8 — belongs to the same family as Epstein–Barr virus, which is responsible for causing infectious mononucleosis and several cancer types and recently has been implicated in the development of multiple sclerosis.

The virally coded oncoprotein vFLIP is known to upregulate the inhibitor of kappa B kinase, or IKK, complex, activating the canonical nuclear factor κB signaling pathway, a major factor in KSHV pathogenesis.

The physical interaction of vFLIP and the IKK kinase regulatory component, IKK gamma, is essential for persistent activation and has been studied widely; however, how the kinase subunits are active mechanistically remains to be determined.

In a recent Journal of Biological Chemistry , Claire Bagn茅ris, Swathi L. Senthil Kumar and collaborators at the Institute of Structural Molecular Biology in London report that vFLIP alone is sufficient to activate the IKK kinase complex. The researchers used a combination of cell-based assays and biophysical and structural biology techniques.

The authors also found weakly stabilized, high-molecular-weight vFLIP-IKKγ assemblies relevant to the activation process.

In the end, this novel study determined that vFLIP-induced NF-κB activation relies upon structurally specific vFLIP–IKKγ multimers that are essential to activate kinase subunits by autophosphorylation.

The proof is in the linker

Iron acts as an electron carrier and a co-factor in many proteins; this makes it an essential nutrient for living organisms, including pathogenic bacteria such as Staphylococcus aureus, which is responsible for deadly nosocomial infections.

The iron-regulated surface determinant system is a family of proteins that sequesters iron from the host to support bacterial growth and is therefore a potential therapeutic target. The surface protein IsdH consists of three near-iron transporter, or NEAT, domains connected by linkers, and it is responsible for capturing hemoglobin.

In a recent Journal of Biological Chemistry , Sandra Valenciano–Bellido and colleagues at the University of Tokyo characterized the linker region between the NEAT2 and NEAT3 domains using multiple biophysical techniques to understand better the role it plays in heme extraction.

The researchers showed that the linker region contributes to the stability of the bound protein and this, in turn, influences the flexibility and orientation of the NEAT3 domain in its interaction with hemoglobin.

The authors suggest this model explains how the linker region facilitates NEAT3 positioning to sequester heme, and they argue that the study adds to researchers’ understanding of the mechanism of heme extraction of human hemoglobin by IsdH.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Isabel Casas

Isabel Casas is the ASBMB’s publications director.

Get the latest from ASBMB Today

Enter your email address, and we鈥檒l send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

RA patient blood reveals joint innerworkings
Journal News

RA patient blood reveals joint innerworkings

July 25, 2025

Researchers in the Netherlands use mass spectrometry to compare the proteome of plasma and synovial fluid in rheumatoid arthritis patients and find a correlation. Read more about this recent paper in Molecular & Cellular Proteomics.

Hope for a cure hangs on research
Essay

Hope for a cure hangs on research

July 17, 2025

Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson鈥檚 fight for survival and hope. Without funding, science can鈥檛 鈥渃atch up鈥 to help the patients who need it most.

Before we鈥檝e lost what we can鈥檛 rebuild: Hope for prion disease
Feature

Before we鈥檝e lost what we can鈥檛 rebuild: Hope for prion disease

July 15, 2025

Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal 鈥 and just getting started.

Defeating deletions and duplications
News

Defeating deletions and duplications

July 11, 2025

Promising therapeutics for chromosome 15 rare neurodevelopmental disorders, including Angelman syndrome, Dup15q syndrome and Prader鈥揥illi syndrome.

Using 'nature鈥檚 mistakes' as a window into Lafora disease
Feature

Using 'nature鈥檚 mistakes' as a window into Lafora disease

July 10, 2025

After years of heartbreak, Lafora disease families are fueling glycogen storage research breakthroughs, helping develop therapies that may treat not only Lafora but other related neurological disorders.

Cracking cancer鈥檚 code through functional connections
News

Cracking cancer鈥檚 code through functional connections

July 2, 2025

A machine learning鈥揹erived protein cofunction network is transforming how scientists understand and uncover relationships between proteins in cancer.